Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Pharma
Merck's Keytruda misses the mark in endometrial cancer study
While Keytruda already boasts a pair of endometrial cancer nods, a recent effort to prove the drug's worth in newly diagnosed patients has failed.
Fraiser Kansteiner
May 9, 2024 10:55am
Merck's BCG monopoly could end
May 3, 2024 10:50am
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market
Apr 24, 2024 8:23am
AACR: Detailed data spark hope for Merck combo in NSCLC
Apr 9, 2024 1:16pm
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
Mar 21, 2024 10:28am
IFF is selling off its pharma solutions business for $2.85B
Mar 19, 2024 10:40am